Ever Supreme Bio Technology Co., Ltd (6712.TWO)

TWD 171.5

(-0.29%)

Market Cap (In TWD)

13.83 Billion

Revenue (In TWD)

758.39 Million

Net Income (In TWD)

539.39 Million

Avg. Volume

498.88 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
166.0-215.0
PE
-
EPS
-
Beta Value
0.304
ISIN
TW0006712003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Po-Ching Lee
Employee Count
-
Website
https://www.ever-supreme.com.tw
Ipo Date
2018-10-26
Details
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.